Novo Nordisk files lawsuit against Eli Lilly over allegedly deceptive GLP-1 dose ads
Novo Nordisk has initiated legal action against Eli Lilly in a U.S. court, alleging that Lilly's recent advertisements misrepresent the dosing of GLP-1 obesity treatments.
The company says the ads compare the highest doses of Lilly's drug with lower doses of Novo's products, creating a false impression of safety and efficacy differences.
Novo characterizes the marketing as "maliciously and deceptively false" and is seeking an injunction to stop the ads and possibly damages.
The dispute highlights the intensifying competition in the rapidly growing obesity drug market, where both firms market GLP-1 therapies.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that